The advent of monoclonal antibodies to Tumor necrosis factor-α (TNF), has revolutionized the treatment in rheumatoid arthritis (RA). These agents have proved to be highly efficacious, making remission an achievable goal in RA. Golimumab is a human monoclonal antibody to TNF, which is approved by the US FDA for the treatment of RA, psoriatic arthritis and ankylosing spondylitis since April 2009. Golimumab is a useful addition to the therapeutic armamentarium against rheumatoid arthritis. It has proven efficacy in RA patients with active disease, despite treatment with methotrexate and also found to be useful in patients who have failed on a prior anti-TNF agent. It offers a reasonable alternative to other anti-TNF drugs like infliximab, adalimumab or etanercept. The short-term safety profile, based on short-term RCTs, is reasonable with no differences in total adverse events, serious infections, cancer, tuberculosis or deaths. However, Long-term surveillance studies are needed for safety assessment.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
The publishing process was fast and convenient. The journal staff were extremely helpful and prompt in responding to questions and issues related to the submission. The online submission and revision process was easy and staff were readily available to answer any questions. The reviewers' comments were insightful, very constructive and extremely helpful. The author interface is user-friendly. The publishing process is fast and convenient. I highly recommend others practitioners and researchers to consider Libertas Academica ...